AIM: To discuss the effect of conbercept in the treatment of polypoid chorioretinopathy(PCV)and its influence on hemorheology.

METHODS: From January 2017 to April 2018, 62 patients with PCV were enrolled in our hospital. According to the difference of treatment, the patients were divided into two groups, 31 cases in each group. The control group was treated with rapunzumab and the observation group with conbercept. Intraocular pressure, BCVA, CMT, SFCT, hemorheology and complications were compared between the two groups.

RESULTS: There was no difference in intraocular pressure, BCVA, CMT and SFCT between the two groups before treatment(P>0.05). With the increase of time, BCVA increased, CMT and SFCT decreased in both groups(P<0.05). BCVA, CMT and SFCT were different between the two groups(P<0.05). There was no difference in intraocular pressure between the two groups before and after treatment(P>0.05). The whole blood high shear viscosity, whole blood low shear viscosity, plasma viscosity and RBC aggregation index in the observation group were lower than those before treatment and lower than those in the control group(P<0.05), and the RBC deformation index was higher than that before treatment and higher than that in the control group(P<0.05). There was no difference in the incidence of complications between the two groups(3% vs 6%, P>0.05).

CONCLUSION: The application of conbercept in PCV can improve the visual acuity, and have a good impact in the hemorheology, reduce the macular edema and other clinical symptoms, and it has high safety and no effect on intraocular pressure.